OOIR: Observatory of International Research

Papers

(The TQCC of Clinical Microbiology Reviews is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
2025 Acknowledgment of CMR Reviewers	261
Extracutaneous sporotrichosis	237
Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections	188
Wild-type distributions of minimum inhibitory concentrations and epidemiological cut-off values—laboratory and clinical utility	187
Integrating whole-genome sequencing into antimicrobial resistance surveillance: methodologies, challenges, and perspectives	147
Erratum for Nyaruaba et al., “Digital PCR Applications in the SARS-CoV-2/COVID-19 Era: a Roadmap for Future Outbreaks”	142
Antibiotic tolerance among clinical isolates: mechanisms, detection, prevalence, and significance	130
The long reach of influenza and other respiratory viruses: from acute epithelial injury to post-viral lung disease	129
The sex hormone-gut microbiome axis: mechanistic drivers of sex-disparate bacterial infection outcomes and precision clinical interventions	120
Progression of antibiotic resistance in Neisseria meningitidis	113
Viral infections and pathogenesis of glaucoma: a comprehensive review	113
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant	104
Emerging hybrid shigatoxigenic and enteropathogenic Escherichia coli serotype O80:H2 in humans and calves	101
Mechanisms of microbial colonization in biofilm-associated infections of hemodialysis catheters and advances in surface modification technologies	94
Intestinal biofilms: pathophysiological relevance, host defense, and therapeutic opportunities	93
HIV-associated cancers and lymphoproliferative disorders caused by Kaposi sarcoma herpesvirus and Epstein-Barr virus	89
Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options	89
A review of post-exposure strategies for high-consequence viral pathogens in the laboratory	89
Decontamination approaches and strategies for the prevention of sink drain-related healthcare-associated infections	87
Canonical fact versus hypothesis testing to decipher transmission of non-tuberculous and tuberculous mycobacteria: a comparative review	80
Henipaviruses: epidemiology, ecology, disease, and the development of vaccines and therapeutics	79
Review of BCG immunotherapy for bladder cancer	79
Non- faecium non- faecalis enterococci: a review of clinical manifestations, virulence factors, and antimicrobial resistance	77
Neisseria gonorrhoeae vaccines: a contemporary overview	75
Clonorchiasis and opisthorchiasis: epidemiology, transmission, clinical features, morbidity, diagnosis, treatment, and control	74

Congenital Syphilis: a Review of Global Epidemiology	71
Drug-resistant Acinetobacter baumannii : mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen	67
Extrapolation and comparison of West Nile virus- and Usutu virus-associated neurological diseases in humans: linking pathology to clinical symptoms	66
Erratum for Cho et al., “Recent advances in therapeutic probiotics: insights from human trials”	64
An unintended consequence: a review of iatrogenic central nervous system mold infections and outbreaks	62
BCG therapy in bladder cancer and its tumor microenvironment interactions	61
Bacterial and fungal infections in persons who inject drugs	60
Serratia species as paratransgenic vehicles: potential applications in vector-borne disease control	58
Fungal diagnostic stewardship in immunocompromised populations: a focus on molds and dimorphic fungi	56
The ecological dynamics of skin microbiota in skin health and diseases	55
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease	53
Implementation of pathogen genomics in clinical microbiology laboratories	53
Diagnosis, Management, and Future Control of Cholera	49
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes	46
Plasmids in Neisseria gonorrhoeae : drivers of DoxyPEP failure and an emerging threat for current therapy	45
Rapid and accurate testing for urinary tract infection: new clothes for the emperor	45
Convalescent plasma for COVID-19: planning for the next pandemic using the worldwide experience	42
The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections	42
Harnessing the host response for precision infectious disease diagnosis	41
Mechanistic insights into the pathogenesis and therapeutic recalcitrance of Staphylococcus aureus osteomyelitis	40
Immunosuppressant imprecision: multidirectional effects on metabolism and microbiome	40
Lyme borreliosis in Brazil: a critical review on the Baggio–Yoshinari syndrome (Brazilian Lyme-like disease)	40
Agnostic Sequencing for Detection of Viral Pathogens	39
Artemisinin-resistant malaria	39
Editorial Board	36